Honors & News
April 30, 2015
Medications are available to treat many of the symptoms of neurodegenerative diseases like multiple sclerosis and Parkinson's disease, but there is no drug or other therapy that improves the memory and cognitive problems that often plague patients. A new start-up company, built around research conducted at the University of Rochester School of Medicine and Dentistry, hopes to change that.
Camber NeuroTherapeutics Inc., founded based on discoveries made in the laboratories of Harris “Handy” A. Gelbard, M.D., Ph.D. and Stephen Dewhurst, Ph.D., plans to attack the cognitive component of neurodegenerative diseases using a completely new approach: stopping the inflammation in the brain, so-called neuroinflammation, that impairs the function of nerve cells and the vast networks they create. These neural networks allow us to store and recall memories, plan and prioritize, focus on particular tasks, and process sensory information.
- Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.J Neurosci. 35, 5271-83. (2015 Apr 01).
- Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.J Virol. 89, 3421-6. (2015 Mar 01).
- Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.Antimicrob Agents Chemother. 58, 7171-81. (2014 Dec 01).